A Randomized Phase Iii Study Of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients (¡ý 65 Years Of Age) With Chronic Lymphocytic Leukemia (CLL)

BH-14-069
Cancer - Leukemia
Syed Ali, MD

 D’Amour Center for Cancer Care

3350 Main Street

Springfield MA 01199


Franklin Medical Center

164 High Street

Greenfield MA 

The purpose of this study is to compare the effects, good and/or bad, of the drug ibrutinib, either alone or in combination with the drug rituximab, with the standard treatment for this disease.
Diagnosis of CLL; no prior treatment
Katie Colbeck
413-794-9875